1. Home
  2. LSAK vs OBIO Comparison

LSAK vs OBIO Comparison

Compare LSAK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • OBIO
  • Stock Information
  • Founded
  • LSAK 1997
  • OBIO 2017
  • Country
  • LSAK South Africa
  • OBIO United States
  • Employees
  • LSAK N/A
  • OBIO N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • OBIO Medicinal Chemicals and Botanical Products
  • Sector
  • LSAK Finance
  • OBIO Health Care
  • Exchange
  • LSAK Nasdaq
  • OBIO Nasdaq
  • Market Cap
  • LSAK N/A
  • OBIO 291.7M
  • IPO Year
  • LSAK N/A
  • OBIO N/A
  • Fundamental
  • Price
  • LSAK $4.99
  • OBIO $8.03
  • Analyst Decision
  • LSAK
  • OBIO Strong Buy
  • Analyst Count
  • LSAK 0
  • OBIO 2
  • Target Price
  • LSAK N/A
  • OBIO $17.00
  • AVG Volume (30 Days)
  • LSAK 44.7K
  • OBIO 247.1K
  • Earning Date
  • LSAK 09-10-2024
  • OBIO 08-08-2024
  • Dividend Yield
  • LSAK N/A
  • OBIO N/A
  • EPS Growth
  • LSAK N/A
  • OBIO N/A
  • EPS
  • LSAK N/A
  • OBIO N/A
  • Revenue
  • LSAK $551,325,000.00
  • OBIO $2,216,000.00
  • Revenue This Year
  • LSAK $9.63
  • OBIO $17.90
  • Revenue Next Year
  • LSAK $8.35
  • OBIO $10.51
  • P/E Ratio
  • LSAK N/A
  • OBIO N/A
  • Revenue Growth
  • LSAK 6.72
  • OBIO N/A
  • 52 Week Low
  • LSAK $3.00
  • OBIO $4.22
  • 52 Week High
  • LSAK $5.33
  • OBIO $11.69
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 62.32
  • OBIO 54.76
  • Support Level
  • LSAK $4.76
  • OBIO $7.48
  • Resistance Level
  • LSAK $4.84
  • OBIO $8.75
  • Average True Range (ATR)
  • LSAK 0.13
  • OBIO 0.60
  • MACD
  • LSAK 0.02
  • OBIO 0.01
  • Stochastic Oscillator
  • LSAK 100.00
  • OBIO 59.03

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Share on Social Networks: